Department of Pharmacy, Drug Design & Discovery Center (D3C), Namur Research Institute for Life Sciences (NARILIS), Namur Thrombosis and Hemostasis Center (NTHC), FUNDP-University of Namur, Namur, Belgium.
Nanotoxicology. 2012 Mar;6(2):213-32. doi: 10.3109/17435390.2011.569096. Epub 2011 Apr 13.
We validated a preclinical toxicological screening assay and provided guidelines to evaluate the potential impact of nanoparticles (NPs) on blood coagulation. Five NPs with various physicochemical properties were studied using several existing methods of clotting times and thrombin generation assays in human normal pool plasma. In both recalcification clotting time (RCT) and calibrated thrombin generation test (cTGT), the NPs exhibited procoagulant activity (SiO₂ ≥ SiC ≥ TiC > CuO > CB) but cTGT was more sensitive and relevant than RCT. Thus, the cTGT appears as a reference assay to investigate the nanoparticle (NP) procoagulant activity in human plasma. It should be used as the reference toxicity test for evaluating the effects of nanomaterials on coagulation cascade. In addition, we also showed that the use of the Pluronic F-108 dispersant and/or the sonication for the NP suspension preparation may mask their procoagulant activity and thus should be avoided.
我们验证了一种临床前毒理学筛选检测方法,并提供了评估纳米颗粒(NPs)对血液凝固潜在影响的指导原则。使用几种现有的凝血时间和凝血酶生成检测方法,研究了具有不同理化性质的 5 种 NPs 在人正常血浆池中的情况。在再钙化凝血时间(RCT)和校准的凝血酶生成试验(cTGT)中,NPs 均表现出促凝活性(SiO₂≥SiC≥TiC>CuO>CB),但 cTGT 比 RCT 更敏感和相关。因此,cTGT 似乎是一种用于研究人血浆中纳米颗粒(NP)促凝活性的参考检测方法。它应该被用作评估纳米材料对凝血级联影响的参考毒性测试。此外,我们还表明,使用 Pluronic F-108 分散剂和/或超声处理 NPs 悬浮液的制备可能会掩盖其促凝活性,因此应避免使用。